



Re: Summary of Formulary Changes Effective April 1, 2026

Dear Health Partner,

We are dedicated to partnering with you to manage our members' care in the most effective way. The CareSource Pharmacy and Therapeutics (P&T) Committee meets regularly to review the Marketplace Drug Formulary and make updates as necessary.

The P&T Committee met recently to update the Formulary. Please review the tables below to see how the Formulary is changing. Additional information about viewing the full Formulary and drug-specific criteria and policies is found at the end of this notice.

There are no drugs that will be added to the Formulary effective April 1, 2026.

Drugs in this table have had a change in how they are covered. This could include a change in their Formulary tier and/or adding or removing a coverage limit. Details are below.

DRUG NAME	COVERAGE CHANGE
BREYNA	Step Therapy Added.
OCALIVA	Policy Archived due to market withdrawal.
REZDIFFRA	Step Therapy Added.
TYSABRI	Step Therapy Updated.
VYNDAQEL	Removed from policy due to market withdrawal.

Drugs in this table were reviewed by the P&T Committee and will have no changes to their Formulary status. Additional clinical updates are noted.

DRUG NAME	NOTES
ANZUPGO	New drug review.
BENLYSTA	New drug review.
BLUJEPA	New drug review.
BRINSUPRI	New drug review.
CAPLYTA	New indication review.
DAWNZERA	New drug review.
ELEVIDYS	Annual review.
EMGALITY	Annual review.
ESBRIET	Annual review.
EVKEEZA	Age expansion review.
GAZYVA	New indication review.
ILARIS	Annual review.
JASCAYD	New drug review.

DRUG NAME	NOTES
JUXTAPID	Annual review.
KOSELUGO	Age expansion and new dosage form review.
LEQEMBI	New dosage form review.
LEQVIO	Annual review.
LINZESS	Age expansion review.
LUMRYZ	Annual review.
LUPKYNIS	Annual review.
LYNKUET	New drug review.
OFEV	Annual review.
OPZELURA	Age expansion review.
PALSONIFY	New drug review.
PAPZIMEOS	New drug review.
PRALUENT	Annual review.
REPATHA	New indication review.
RHAPSIDO	New drug review.
RINVOQ	Annual review.
SAPHNELO	Annual review.
SIMPONI	Age expansion review.
SKYSONA	New indication review.
TEZSPIRE	New indication review.
TOCILIZUMAB	Annual review.
TREMFYA	Age expansion review.
UZEDY	New indication review.
VIZZ	New drug review.
VONVENDI	Age expansion review.
VYJUVEK	Age expansion review.
WAKIX	Annual review.
WAYRILZ	New drug review.
WEGOVY	New indication review.
WINREVAIR	Annual review.
XROMI	Age expansion and new dosage form review.
XYREM	Annual review.
XYWAV	Annual review.
YIMMUGO	New drug review.
YUFLYMA	Age expansion review.
ZEVASKYN	New drug review.
ZORYVE 0.05%	Age expansion review.

We can provide a list of CareSource members taking any medication upon request. Please email your request to PharmacyConversionProgram@CareSource.com. Include medication names and your secure fax number in your request. We will fax you a list of your patients who were prescribed these medications.

We know patient care is of the utmost importance to you. We sent a letter to members who may be negatively impacted due to these changes. In our letter, we recommended members contact their prescriber if they have questions.

Additional Resources

You can view the **full CareSource Marketplace Drug Formulary** on the Provider pages at CareSource.com. Select “Drug Formulary” from the “Tools & Resources” menu under the “Providers” drop down.

The [Drug Formulary page](#) also includes a link to our online Formulary Search Tool where you can find **drug coverage criteria** and links to applicable clinical and administrative policies.

We recognize each patient is unique, and we appreciate your partnership in transitioning members who may be impacted by the Formulary changes above. We are here to help you with any questions. Call Provider Services at **1-833-230-2101**. We are open Monday through Friday, 8 a.m. to 6 p.m. Eastern Time (ET).

Thank you for being a CareSource health partner.

Sincerely,

CareSource Marketplace

Multi-EXC-P-3633600-V.6